Healthcare of Ontario Pension Plan Trust Fund Has $17.05 Million Holdings in Axonics, Inc. (NASDAQ:AXNX)

Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Axonics, Inc. (NASDAQ:AXNX) by 9.2% in the 3rd quarter, Holdings Channel reports. The fund owned 245,000 shares of the company’s stock after buying an additional 20,700 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Axonics were worth $17,052,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in AXNX. Price T Rowe Associates Inc. MD boosted its position in Axonics by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 28,897 shares of the company’s stock valued at $1,994,000 after buying an additional 1,828 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Axonics by 637.7% in the 1st quarter. Janus Henderson Group PLC now owns 178,322 shares of the company’s stock worth $12,298,000 after purchasing an additional 154,149 shares in the last quarter. QRG Capital Management Inc. boosted its stake in shares of Axonics by 20.0% during the second quarter. QRG Capital Management Inc. now owns 14,415 shares of the company’s stock valued at $969,000 after purchasing an additional 2,405 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Axonics by 379.6% during the second quarter. SG Americas Securities LLC now owns 8,321 shares of the company’s stock worth $559,000 after purchasing an additional 6,586 shares during the last quarter. Finally, Granite Bay Wealth Management LLC acquired a new position in shares of Axonics in the second quarter valued at approximately $1,698,000. Institutional investors own 99.48% of the company’s stock.

Analysts Set New Price Targets

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research note on Friday, November 8th. Eight research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $71.00.

Axonics Stock Performance

NASDAQ:AXNX opened at $70.98 on Friday. The company has a market capitalization of $3.63 billion, a PE ratio of -591.45 and a beta of 0.82. The company has a 50 day simple moving average of $70.21 and a two-hundred day simple moving average of $68.79. Axonics, Inc. has a fifty-two week low of $55.09 and a fifty-two week high of $71.05.

Insider Buying and Selling at Axonics

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total transaction of $205,523.01. Following the completion of the sale, the chief financial officer now owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. This represents a 6.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.85% of the company’s stock.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.